Dynavax Technologies Corp - Company Profile
Powered by 
All the sales intelligence you need on Dynavax Technologies Corp in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Dynavax Technologies Corp fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Dynavax Technologies Corp.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Dynavax Technologies Corporation (Dynavax), a subsidiary of Sanofi is a biopharmaceutical company focused on discovering, developing, and commercializing innovative vaccines and immune-based therapeutics. Its approach centers on leveraging the body’s innate and adaptive immune systems by stimulating toll-like receptors (TLRs). In particular, Dynavax works on modulating endosomal TLRs—transmembrane proteins that help trigger innate immune defenses and shape longer-term adaptive immune responses.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Dynavax is progressing a pipeline of distinct product candidates that use its CpG 1018 adjuvant to create enhanced vaccines for diseases with unmet medical needs. These efforts include vaccine candidates in development for shingles and plague, along with other vaccine programs in preclinical development. The company also participates in partnerships to advance adjuvanted vaccines using CpG 1018 and has worked with organizations on COVID-19 vaccine development. Dynavax is moving forward with a pipeline of investigational vaccine candidates, including shingles and plague programs, in Phase I and Phase II trials. The R&D group oversees ongoing research and development of HEPLISAV-B and the CpG 1018 adjuvant, clinical candidates, and preclinical studies. This includes controlling costs under agreements with contract research organizations, contract manufacturing organizations, and service providers supporting clinical studies, plus expenses related to preclinical work and regulatory operations. The company maintains key technology alliances with partners such as Valneva Austria GmbH, Medigen Vaccine Biologics Corporation, and Colorado State University Research Foundation.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer